We are a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. Our proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (“NETs”), which are involved in cancer growth, metastasis and progression, and contribute to immunotherapy, chemotherapy and radiotherapy resistance.
Partnerships Pharmsynthez (collaboration agreement to develop and launch in limited markets; Phase II(b)/III trial in Russia with patient recruitment completed 2020 and a Russian registration dossier filed); Serum Institute of India (collaboration agreement; completed Phase I/II trials in India for in-center-dialysis patients and not actively pursuing further development)
Indications
Anemia in chronic kidney disease(Phase 2/3)
Status note ErepoXen is in a partner-led Phase II(b)/III development path in Russia; Xenetic is not pursuing clinical development of ErepoXen itself but continues to entertain out-license opportunities in its licensed territories.
Partnerships CLS Therapeutics Ltd. (exclusive license and sublicense agreements to develop its interventional DNase technology); PeriNess (clinical trial services agreement to advance development with chemotherapy and immunotherapy); UVA (collaboration to advance the systemic DNase program); Scripps Research (DNase research collaboration)
Indications
Pancreatic carcinoma(Preclinical)
Colorectal cancer(Preclinical)
Locally advanced or metastatic solid tumors(Preclinical)
Status note Focused on advancing the systemic DNase program into the clinic as an adjunctive therapy for pancreatic cancer and other locally advanced or metastatic solid tumors; none of the company's drug candidates have received regulatory marketing authorization.
DNase-armored CAR T program
Preclinical · ActiveModality: DNase-armored CAR T
Partnerships Scripps Research (in vivo CAR T model collaboration)
Indications
Solid tumors(Preclinical)
Status note Pre-clinical development completed; mechanism-of-action and translational studies and CAR T in vivo models remain ongoing.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.